about
Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women?Chronic hepatitis C: This and the new era of treatmentPrevalence of Hepatitis C Among Australian Aboriginal and Torres Strait Islander people: A Systematic Review and Meta-AnalysisCost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisonsHCV infected prisoners: should they be still considered a difficult to treat population?Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis CA descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners.Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional studyAssessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.Evaluation of the regional nurse-supported hepatitis C shared care program in Western Australia: a mixed methods study.Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort CollaborationA multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care.Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levelsHigh burden of hepatitis C & HIV co-infection among people who inject drugs in Manipur, Northeast India.Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsMouse models for liver cancer.Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection.Advances in the management of hepatitis C.Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis.Discrimination by health care workers versus discrimination by others: countervailing forces on HCV treatment intentions.Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?Health workers' support for hepatitis C treatment uptake among clients with a history of injecting.Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.Lower life expectancy among people with an HCV notification: a population-based linkage study.Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents.The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.How cost-effective is hepatitis C virus treatment for people who inject drugs?Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs.
P2860
Q24658656-5638D03E-E13F-4F44-B8A8-BEC6BC00FA3CQ26775011-951AB76E-958F-42C3-BC8B-D2232E3C54AFQ28077377-507C7D09-EBD7-420D-9103-E2F87A8E82BFQ28681550-2430B8B5-413E-43B8-8AB3-A654A2D5532CQ34941459-FFED98BB-CFC7-4B15-AEC2-03FA5AAC2093Q35031753-189BBDC5-1114-45B3-ABF6-BDF5BBCD7FFEQ35105946-64BF1A1C-7EC4-4F02-A80B-45471279B0E3Q35154639-808A177C-7E82-477E-BDD3-A085B5036DA3Q35565944-F24409C6-045D-4012-BDE3-8D5960539D39Q35782742-EBF7B940-C31E-41E0-A8B7-38ECFA395B8BQ35864236-5ACA8F26-A9FD-4F72-8F3F-873E851BDDD8Q36161813-4C511093-9907-47B0-A267-70E523758E79Q36590782-B95F18DB-64A0-47D3-ADFC-B434DE1F2CA3Q36966164-8893EC7E-862F-4136-89A3-4AD2DC41EE02Q37042425-7668F639-E2ED-4E93-B47A-DA09367EDB16Q37540482-A8BE6D4A-1F92-4E5E-9CFE-0CE4A805BDB3Q37601315-4623328E-F0EE-410C-8AFE-6B78E4B6278AQ38083387-A04E91D4-53E6-42C1-ABE7-243CF2762E81Q38123947-8AEE8274-BC46-478F-940D-344B7E6B778AQ38170564-36ADF7B4-1D48-4C58-BB2C-371BD380A62CQ38233245-1826FDBB-B036-4DF1-87B9-8A0C6A7C09B2Q38407675-8BF5F2C6-B577-4F64-9537-047F2E421B3CQ38573508-FC9AF44F-C8BF-4D0B-82C2-6AAA6A638C9DQ39138754-C4B322B4-8A26-4623-8584-619402B38307Q39182010-FC67C30A-1F72-4D6E-9CBD-E06A3E0BBAEBQ39269740-B5081D28-F1F6-464E-9353-14EC15B2E2EEQ40042851-7347EC58-AAFC-45DB-8CE3-57CD2C129E80Q40364008-CEA8B8F2-0250-42AE-96FC-E865569FF230Q40789247-A0760DD7-D7C0-436F-8D69-3B1483377092Q40931707-C119B73B-CB01-4B35-BB2F-7583E1BEA0CEQ41489816-A23DAFBE-74B3-4D3A-9226-83673DAB75A7Q41496602-9854D91A-606E-4FB4-940E-03DBBA30FF6EQ42218829-CC9550FA-5343-470A-8F72-C5FC5EB18EA3Q42220208-7482D7F0-B973-4EB2-90A7-C8EB8171F9FAQ42259402-D924ADF2-F405-49A1-BF3F-E717D61B70B3Q42955909-25BDC3C7-2D3F-4B0D-8180-87681C4E920AQ42986757-DCDBD268-123F-4BF1-AD82-09B6C3BB4935Q43688887-E74BD2DD-9FB9-4FB5-BFD8-4E03E8923B0EQ45333992-E7534912-8EE8-4D15-A14E-158950C160FD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The changing therapeutic landscape for hepatitis C.
@en
type
label
The changing therapeutic landscape for hepatitis C.
@en
prefLabel
The changing therapeutic landscape for hepatitis C.
@en
P356
P1476
The changing therapeutic landscape for hepatitis C.
@en
P2093
Gregory J Dore
P304
P356
10.5694/MJA11.11531
P407
P577
2012-06-01T00:00:00Z